Graham W. Neill

Reading, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 09, 2025

Treatment of Haemophilia A Without Inhibitors: Real-World Treatment Patterns and Clinical Outcomes in the US.

Treatment of Haemophilia A Without Inhibitors: Real-World Treatment Patterns and Clinical Outcomes in the US.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 18, 2025

Challenges and Opportunities in Post-Marketing Reporting of Factor VIII Inhibitors With Efanesoctocog Alfa.

Challenges and Opportunities in Post-Marketing Reporting of Factor VIII Inhibitors With Efanesoctocog Alfa.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: July 28, 2025

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.

Journal: Journal of thrombosis and haemostasis : JTH

Published: February 06, 2025

Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies.

Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND-1 and XTEND-Kids Studies.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: November 14, 2024

Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.

Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.

Journal: American journal of hematology

Published: August 06, 2024

Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.

Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.

Journal: Carcinogenesis

Published: January 29, 2021

Dynamic chromatin accessibility landscape changes following interleukin-1 stimulation.

Dynamic chromatin accessibility landscape changes following interleukin-1 stimulation.

Journal: Epigenetics

Published: August 04, 2020

A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors.

A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors.

Journal: Cancer research

Published: September 20, 2017

Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function.

Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function.

Journal: The Journal of pathology

Published: October 24, 2013

The oncogenic GLI transcription factors facilitate keratinocyte survival and transformation upon exposure to genotoxic agents.

The oncogenic GLI transcription factors facilitate keratinocyte survival and transformation upon exposure to genotoxic agents.

Journal: Oncogene

Published: December 12, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026